I'm not robot	
	reCAPTO

Continue

## New passport documents list pdf

```
Holiday travel can be stressful: Even before you squeeze into your assigned plane seat, you'll have to contend with traffic, long security lines, and delayed flights. One thing you can do to eliminate some of that anxiety is make sure all your travel documents are in order. "I think one of the
biggest mistakes people make is waiting to check their documents until they're heading to the airport," says Liana Corwin, travel expert at Hopper. "It's really something you need to look into while you're making your plan." Getting turned away at the airport is potentially an expensive loss,
especially if you had an international ticket. And not planning ahead means you may have to incur costs like getting your passport expedited. So, before you head to the airport, here's what you need to know about all the documents you may need for a smooth trip. You may know that you
can't travel with an expired passport, but it may come as an unpleasant surprise that many countries won't allow you to travel with a passport that is going to expire in less than six months. If your passport is set to expire in the next six months or so, you should renew it now. Typically,
renewing a passport takes six to eight weeks. If you need yours sooner, contact the State Department, Corwin says. "You just need to show them when you plan to travel and they will expedite [your passport to you] based on those dates," she says. "Of course, you have to pay a little extra
but the State Department is good about that."Right now the price to renew and expedite a passport is $170, versus $110 for regular processing. Along with a valid passport, you'll need a visa to enter many countries, says Jesse Neugarten, CEO of Dollar Flight Club. "Some countries you
don't need a visa for a stay of up to 30 days," he says. Other countries won't let you in at all without one. The State Department's country information page is a great place to find all the information you need to get into a foreign country without a hassle. For example, if you are traveling to
Vietnam, a quick search on the State Department's database will tell you that you don't need any vaccinations, but you do need a tourist visa and your passport must be valid for at least the next six months. To get into Argentina, though, your passport only needs to be valid during the time of
entry and you can stay for up to 90 days without a visa. You also won't need any vaccinations. I think one of the biggest mistakes people make is waiting to check their documents until they're heading to the airport. It's really something you need to look into while you're making your
plan.Costs and timelines to obtain a visa vary. For example, with Vietnam it takes two days to process a visa, and you'll pay a $45 fee for one-time entry. If you're going to Turkey, a visa takes 12 hours to process and costs $20. Also be sure to check whether you can get the visa upon arrival
or whether you have to plan ahead. It's usually cheaper if you get the visa before getting to the destination, Neugarten says. An international driver's license allows you to drive in another country, and anyone with a valid U.S. driver's license can get one. AAA is one of two entities that are
allowed to administer an international driver's license. The other is the American Automobile Touring Alliance, or AATA. It's "really easy" to get one at an AAA branch, Neugarten says. All you need to do is fill out an application and bring two passport pictures along with your U.S. driver's
license. It will cost $20 and you will get it in 10 to 15 business days. Rental companies in other countries might let you don't have an
international driver's license, he says. That will most likely cost you more than the price of just getting the license. Starting October 1, 2020, if you want to use your driver's license as identification to get you onto a commercial domestic flight, you'll need one that's Real ID compliant. That
means it's in line with new government-mandated security measures and has a "REAL ID compliant star marking," according to the Homeland Security FAQ page. Almost all states are already issuing security-compliant Real ID cards, Corwin says. "You'll have the option of renewing [your
driver's license] as a driver's license or a Real ID, which is a driver's license. You should get it as a Real ID now because in less than a year's time, that's the ID you're gonna need."You can get a Real ID online or at the DMV, and costs will vary based on what state you live in. In
Pennsylvania, a Real ID is $30. In Georgia, it is $20. You should get it as a Real ID now because in less than a year's time, that's the ID you're gonna need. If you're traveling with your minor children, many airlines require some form of ID for them, depending on how old they are and the
airline. For example, if you are traveling with someone under the age of 2, Southwest Airlines requires that you present the child's birth certificate, school ID, or Social Security card should suffice, Neugarten says."If you are traveling with your child and you
don't have the same last name as them, you may be required to have a document from your partner who has the same last name as your child, saying it's OK to travel," Corwin says. And if you are a single parent and don't have the same last name as your child, it's smart to bring
documentation that proves you are their parent, like a birth certificate, just in case. If you're lacking any of the documentation you need, don't panic, Corwin says. Often, you can expedite whatever documents you need, if you're willing to pay additional fees: "There are ways to fix it." More
from Grow: A passport is an official document that is used for travel purposes. In the majority of cases, passports are issued by governments, and serve to certify an individual's identity and nationality. Passports are typically used for international travel, and allow customs agents to grant or
deny entry to the passport holder. They provide information such as the holder's name(s), date and place of birth, a photograph, signature, and other identifying details, such as weight, height, and eye color. Most passports include a sequence of numbers or letters which is used to quickly
identify and/or communicate data about the passport holder. Passport technology is moving towards including biometric data, with a chip embedded in the document that would make passports more difficult to replicate illegally. Passport holders are entitled to enter the country which issued
the passport. However, in a small number of cases, holders of passports to a given country may be citizens who do not have the right to residency. A passport is a document and does not necessarily indicate a strict set of rights. Some passports may indicate diplomatic or official status,
entitling the individual protection from the country's consulate or political immunity. Passports are used in international travel to allow holders to enter different countries. In many cases, they must be accompanied by a visa, depending on the length and nature of the trip. A country that does
not recognize another country or is embroiled in a political dispute with another country may choose to prohibit the use of their own passport for travel to that country, and in addition may prohibit holders of passports from that country to enter their own country. Standard passports are not
the only travel document recognized internationally. Other documents may enable the holder to travel to countries that recognize such documents. For instance, stateless individuals may not possess a passport, but they may possess a travel document indicating refugee status or a "Nansen
passport," which was once used to enable the holder to travel to countries that recognized that passport and potentially return to the country where the passport was issued. Non-nationals may also be holders of passports are also an accepted form of proof of identity in the home
country. Types of Passports: Regular passport: This is the most common type of passport. It may also be referred to as a tourist passport. It is typically issued to a citizen or another national. In some cases, children are registered on their parent's passport. Official passport: An official passport
may be issued to members of government for official travel purposes. Diplomatic passport: These passports are issued to diplomats of a particular country, as well as any dependents they may have, for the purpose of international travel and/or residency. Diplomats may also be granted
diplomatic immunity by their host country; however, this is not an automatic condition of holding a diplomatic passport. An emergency passport, which may be referred to as a temporary passport or a laissez-passer passport, is used for emergency purposes, when other
documents have been stolen or lost and there is no time to find a replacement. The document needs list is a list of key forms and documents a person taking out a mortgage needs to have on hand so that the lender can determine whether it will extend a mortgage to her. Typical items
include paycheck stubs, tax returns, bank statements, and other data proving financial worth and creditworthiness. Deeper definition that proves an individual is capable of making his or her loan payments on time. Underwriters have the job of
verifying each detail and document. They need to look at how much income an individual has, how much debt is present, and how the individual manages money. To do this, the underwriters need a significant amount of actual documentation to prove the claims made by the borrower. They
provide a document needs list that outlines which documents a potential borrower needs to obtain and submit to them in order to process the loan. Common types of documents include paycheck stubs, tax returns and most recent W-2s, bank and retirement account statements, insurance
policies, and stock options. But every borrower has a different financial background, and every item on the document needs list might not be relevant in every case. To get started in purchasing a home, visit Bankrate's mortgage calculator and learn how much you can expect to pay.
Document needs list example The Jacobs hope to purchase a home. They find one they like and submit a bid on it. They find a mortgage lender to pay for their home, who gives them a document needs list that illustrates all the documents the lender will accept as proof of their ability to pay
back the loan. The Jacobs submit only the documents that are relevant to them, so they can safely ignore the lender's request for stock options, of which they have none, and pension benefits, which they don't receive. Once the relevant documents are submitted, they need to wait for their
mortgage lender to approve them. In this section: Guidances (Drugs) Center For Drug Evaluation and Research List of Guidance Documents represent the Agency's current thinking on a particular subject. They do not create or confer any rights for or on any person
and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes, regulations, or both. For information on a specific guidance document, please contact the originating office (see footnote 1 in recent
guidances), or contact the Division of Drug Information in the Office of Training and Communications. Office of Training and Communications Division of Drug Information 10903 New Hampshire Avenue Silver Spring, MD 20993 Table of Contents (by Subject
Category) Advertising Biopharmaceutics Biosimilars Clinical Antimicrobial CMC-Chemistry Clinical Medical Clinical Pharmacology CMC - Microbiology Combination Products (Drug/Device/Biologic) Current Good Manufacturing Practices/Compliance Drug Safety Electronic Submissions Generic
Drug Good Review Practices ICH INDIndustry LettersLabeling Modernization Act OTC Pharmacology/ToxicologyProcedural Small Entity Compliance Guides User FeeAdvertisingAdvertisingIssued DateAerosol Steroid Product Safety Information in Prescription Drug Advertising and
Promotional Labeling (I)1/12/1998Consumer-Directed Broadcast Advertisements (I)8/9/1999Industry-Supported Scientific and Educational Activities (I)12/3/1997Product Name Placement, Size, and Prominence in Advertising & Promotional Labeling1/25/2012Advertising DraftIssued
Date "Help-Seeking" and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms (I)2/10/2004Accelerated Approval Products -- Submission of Promotional Materials (I)3/26/1999Brief Summary: Disclosing Risk Information in Consumer-Directed Print
Advertisements(I)2/10/2004Direct-to-Consumer Television Advertisements -- FDAAA DTC Television Ad Pre-Dissemination Review Program3/13/2012Presenting Risk Information in Prescription Drug and Medical Device Promotion (I)5/27/2009Promoting Medical Products in a Changing
Healthcare Environment; Medical Product Promotion by Healthcare Organizations or Pharmacy Benefits Management Companies (PBMs) (I)1/5/1998BiopharmaceuticsIssued DateBioanalytical Method Validation (I)5/23/2001Bioavailability and Bioequivalence Studies for Orally Administered
Drug Products - General Considerations (Revised) (I)3/19/2003 Corticosteroids, Dermatologic (topical) In Vivo (I)6/2/1995 Dissolution Testing of Immediate Release Solid Oral Dosage Forms (I)8/25/1997 Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In
Vitro/In Vivo Correlations (I)9/26/1997Food-Effect Bioavailability and Fed Bioequivalence Studies (I)1/31/2003Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro (I)6/27/1989Statistical Approaches to Establishing Bioequivalence (I)2/2/2001Waiver of In Vivo Bioavailability
and Bioequivalence Studies for Imediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (I)8/31/2000Biopharmaceutics DraftIssued DateAntifungal (topical) (I)2/24/1990Antifungal (vaginal)2/24/1990Bioavailability and Bioequivalence Studies for Nasal
Aerosols and Nasal Sprays for Local Action (I)4/3/2003Biosimilarity DraftQuality Considerations in Demonstrating Biosimilarity to a Reference Product2/15/2012Scientific Considerations in Demonstrating Biosimilarity to a Reference Product2/15/2012Scientific Considerations in Demonstrating Biosimilarity to a Reference Product2/15/2012Guidance for Industry on
Biosimilars: Q & As Regarding Implementation of the BPCI Act of 20092/15/2012Chemistry, Manufacturing, and Controls (CMC)Issued DateBotanical Drug Products (I)6/9/2004Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products
(I)7/24/1997Changes to an Approved NDA or ANDA (Revised) (I)4/8/2004Changes to an Approved NDA or ANDA: Questions and Answers (I)1/22/2001Changes to an Approved New Drug Application or Abbreviated New Drug Application; Specifications -Use of Enforcement Discretion for
Compendial Changes (I)11/22/2004Container Closure Systems for Packaging Human Drugs and Biologics (I)7/7/1999Demonstration of Comparability of Human Biologics (I)3/26/1996Development of New Stereoisomeric
Drugs (I)5/1/1992Drug Master Files (I)9/1/1989Drug Master Files for Bulk Antibiotic Drug Sustances (I)11/29/1999Environmental Assessment of Human Drug and Biologics Applications (I)7/27/1998Filing Protocol - Residual Solvents11/25/2009Format and Content for the CMC Section of an
Annual Report (I)9/1/1994Format and Content of the Microbiology Section of an Application* (I)2/1/1987Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting (I)10/11/2011IND Meetings for Human Drugs and Biologics; Chemistry,
Manufacturing, and Controls Information (I)5/25/2001INDs for Phase 2 and 3 Studies; Chemistry, Manufacturing, and Controls Information (I)5/20/2003Monoclonal Antibodies Used as Reagents in Drug Manufacturing (I)3/29/2001Nasal Spray and Inhalation Solution, Suspension, and Spray
Drug Products -- Chemistry, Manufacturing, and Controls Documentation (I)7/5/2002NDAs: Impurities in Drug Substances (I)2/25/2000Orally Disintegrating Tablets (I)12/16/2008PAC-ALTS: Postapproval Changes - Analytical Testing Laboratory Sites (I)4/28/1998Residual Drug in
Transdermal and Related Drug Delivery Systems (I)8/16/2011Size of Beads in Drug Products Labeled for Sprinkle5/2/2012Submitting Documentation for the Manufacturing of and Controls for Drug Products* (I)2/1/1987Submitting Samples and Analytical Data for Methods Validation*
(I)2/1/1987Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Products (I)2/1/1987SUPAC-IR Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and
In Vivo Bioequivalence Documentation (I)11/30/1995SUPAC-IR Questions and Answers (I)2/18/1997SUPAC-IR/MR: Immediate Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum (I)2/26/1999SUPAC-MR: Modified Release Solid Oral Dosage
Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and In Vivo Bioequivalence Documentation (I)10/6/1997SUPAC-SS - Nonsterile Semisolid Dosage Forms; Scale-Up and Postapproval Changes: Chemistry, Manufacturing, Alexandria Changes: Chemistry, Manufacturing, Alexandria Changes: Chemistry, Manufacturing, Alexandria Changes: Chemistry, Manufacturing, Alexandria Changes: Chemistry, Manuf
and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation (I)6/13/1997The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform (I)12/20/2000Validation of Chromatographic Methods -- Reviewer's Guidance
(I)11/1/1994Chemistry, Manufacturing, and Controls (CMC) DraftIssued DateAnalytical Procedures and Methods Validation (I)8/30/2000Assay Development for Immunogenicity Testing of Therapeutic Proteins (I)12/4/2009CMC Postapproval Manufacturing Changes Reportable in Annual
Reports (I)6/25/2010Comparability Protocols - Chemistry, Manufacturing, and Controls Information (I)2/25/2003Drugs, Biologics, and Medical Devices Derived From Bioengineered Plants for Use in Humans and Animals (I)9/12/2002Interpreting Sameness of Monoclonal Antibody Products
Under the Orphan Drug Regulations (I)7/26/1999Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation
(I)8/21/2002Metered Dose Inhalers (MDI) and Dry Powder Inhalers (DPI) Drug Products (I)11/19/1998Non-Penicillin Beta-Lactam Risk Assessment: A CGMP Framework3/15/2011Regulatory Classification of Pharmaceutical Co-Crystals12/1/2011Submitting Supporting Chemistry
Documentation in Radiopharmaceutical Drug Applications*11/1/1991SUPAC-SS: Nonsterile Semisolid Dosage Forms Manufacturing Equipment Addendum (I)1/5/1999Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation8/29/2011Clinical AntimicrobialIssued DateAntiretroviral
Drugs Using Plasma Human Immunodeficiency Virus Ribonucleic Acid Measurements -Clinical Considerations for Accelerated and Traditional Approval (I)11/1/2002Antiviral Product Development -Conducting and Submitting Virology Studies to the Agency6/5/2006Antibacterial Drug
Products: Use of Noninferiority Trials to Support Approval11/29/2010Clinical Development and Labeling of Anti-Infective Drugs (Systemic) (I)9/1/1977Influenza: Developing Drugs for Treatment and/or Prophylaxis4/13/2011Role
of HIV Drug Resistance Testing in Antiretroviral Drug Development (I)10/31/2007 Clinical Antimicrobial DraftIssued DateAcute Bacterial Exacerbation of Chronic Bronchitis in Patients with COPD; Developing Antimicrobial Drugs for Treatment (I)8/22/2008 Acute Bacterial Meningitis;
Developing Antimicrobial Drugs for Treatment (I)7/22/1998Acute Bacterial Otitis Media: Developing Drugs for Treatment (I)1/18/2008Acute Bacterial Sinusitis: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (I)1/30/2007Acute Bacterial Skin and Skin Skin 
Treatment7/22/1998Acute or Chronic Bacterial Prostatitis; Developing Antimicrobial Drugs for Treatment (I)8/27/2010Acute Otitis Media; Developing Acute Otitis Media; Developing Acute Otitis Media; D
Related Bloodstream Infections - Developing Antimicrobial Drugs for Treatment (I)10/18/1999Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment9/14/2010Community Acquired Pneumonia; Developing Antimicrobial Drugs for Treatment
(I)7/22/1998Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment (I)3/20/2009Complicated Urinary Tract Infections: Developing Drugs for Treatment2/24/2012Developing Antimicrobial Drugs -General Considerations for Clinical Trials (I)7/22/1998Developing
Antimicrobial Drugs to Treat Inhalational Anthrax (Post-Exposure) (I)3/18/2002Empiric Therapy of Febrile Neutropenia; Developing Antimicrobial Drugs for Treatment (I)7/22/1998Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products
(I)2/17/1997Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults: Developing Drugs for Treatment (I)10/5/2009Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment11/29/2010Lyme Disease; Developing
Antimicrobial Drugs for Treatment (I)7/22/1998Microbiological Data for Systemic Antibacterial Drug Products - Development, Analysis, and Presentation (I)9/17/2009Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention8/23/2011Nosocomial
Pneumonia - Developing Antimicrobial Drugs for Treatment (I)7/22/1998Secondary Bacterial Infections of Acute Bronchitis - Developing Antimicrobial Drugs for Treatment (I)7/22/1998Smallpox (Variola) Infection: Developing Drugs for Treatment or Prevention (I)11/23/2007Streptococcal
Pharyngitis and Tonsillitis; Developing Antimicrobial Drugs for Treatment (I)7/22/1998Uncomplicated and Complicated Skin and Skin Structure Infections; Developing Antimicrobial Drugs for Treatment (I)7/22/1998Uncomplicated Gonorrhea -- Developing Antimicrobial Drugs for Treatment
(I)7/22/1998Uncomplicated Urinary Tract Infections - Developing Antimicrobial Drugs for Treatment (I)7/22/1998Vaccinia Virus -- Developing Drugs to Mitigate Complications From Smallpox Vaccination (I)3/9/2004Vuvlovaginal Candidiasis - Developing Antimicrobial Drugs for Treatment
(I)7/22/1998Clinical MedicalIssued DateAcceptance of Foreign Clinical Evaluation (I)3/13/2001Antianxiety Drugs -- Clinical Evaluation (I)9/1/1977Antiepileptic Drugs (adults and children) -- Clinical Evaluation (I)1/1/1981Available Therapy
(I)7/23/2004Calcium DTPA and Zinc DTPA Drug Products -- Submitting a New Drug Application (I)8/13/2004Cancer Drug and Biological Products - Clinical Data in Marketing Applications (I)10/5/2001Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment
(I)6/2/2006Clinical and Statistical Sections of an Application --Format and Content* (I)7/1/1988Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA) (I)2/17/1999Clinical Endpoints for the Approval of Cancer Drugs and
Biologics (I)Collection of Race and Ethnicity Data in Clinical Trials for FDA Regulated Products (I)5/16/2007Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products
(I)11/20/1995Developing Medical Imaging Drug and Biological Products, Part 1: Conducting Safety Assessments (I)6/22/2004Developing Medical Imaging Drug and Biological Products, Part 3:
Design, Analysis, and Interpretation of Clinical Studies (I)6/22/2004Development and Use of Risk Minimization Action Plans (I)Development of Vaginal Contraceptive Drugs (NDA) (I)Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
(I)12/19/2008Establishing Pregnancy Exposure Registries (I)9/23/2002Evaluating the Risks of Drug Exposure in Human Pregnancies4/28/2005Evaluation of the Effects of Orally Inhaled and Intranasal Corticosteroids on Growth in Children (I)3/6/2007Exocrine Pancreatic Insufficiency Drug
Products-Submitting New Drug Applications (I)4/14/2006FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products (I)2/2/1999FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer (I)1/29/1991Formatting, Assembling and Submitting
New Drug and Antiobiotic Applications* (I)2/1/1987General Anesthetics -- Clinical Evaluation (I)5/1/1982General Considerations for the Clinical Evaluation of Drugs in Infants and Children (I)9/1/1977Good
Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (I)3/29/2005Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research4/4/2011Hypnotic Drugs -- Clinical Evaluation
(I)9/1/1977IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer (Revised) (I)1/15/2004Integration of Dose-Counting Mechanisms Into Metered-Dose Inhaler Drug Products (I)3/13/2003Internal Radioactive Contamination - Development of
Decorporation Agents (I)3/2/2006 Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment5/31/2012 Levothyroxine Sodium Tablets -- In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing (I)3/8/2001 Local Anesthetics -- Clinical Evaluation
(I)5/1/1982MDI and DPI Drug Products -- Clinical Development and Programs (I)9/19/1994Oncologic Drugs Advisory Committee Discussion on FDA Requirements for Approval of New Drugs for Treatment of Colon and Rectal Cancer (I)4/19/1988Oncologic Drugs Advisory Committee
Discussion on FDA Requirements for Approval of New Drugs for Treatment of Ovarian Cancer (I)4/13/1988 Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (I)12/9/2009 Pediatric Use Supplements -- Content and Format
(I)5/24/1996Postmarketing Adverse Experience Reporting for Human Drugs and Licensed Biological Products; Clarification of What to Report (I)8/27/1997Postmarketing Reporting of Adverse Drug Experiences (I)3/1/1992Premarketing Risk Assessment (I)3/29/2005Preparation of
Investigational New Drug Products (Human and Animal) (I)11/1/1992Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (I)5/15/1998Prussian Blue for Treatment of Internal Contamination With Thallium or Radioactive Cesium (I)2/4/2003Psychoactive Drugs
in Infants and Children -- Clinical Evaluation (I)7/1/1979Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs (I)7/22/1993Study of Drugs Likely to be Used in the Elderly (I)11/1/1989Submission of Abbreviated Reports and Synopses in Support of Marketing
Applications (I)9/13/1999Summary for New Drug and Antibiotic Applications -- Format and Content* (I)2/1/1987Systemic Lupus Erythematosus - Developing Drugs for Treatment (I)6/22/2010The Radioactive Drug Research Committee: Human Research Without An Investigational New Drug
Application (I)8/2/2010Clinical Medical DraftIssued DateAcne Vulgaris: Developing Drugs for Treatment (I)9/19/2005Allergic Rhinitis: Clinical Development Programs for Drug Products (I)6/21/2000Anti-Anginal Drugs -- Clinical Evaluation (I)1/1/1989Anti-Arrhythmic Drugs -- Clinical
Evaluation 7/1/1985 Antihypertensive Drugs -- Clinical Evaluation 5/1/1988 Assessment of Abuse Potential of Drugs (I)1/27/2010 Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment (I)11/9/2007 Clinical Development Programs for Drugs, Devices, and Biological Products
Intended for the Treatment of Osteoarthritis (OA) (I)7/15/1999Clinical Evaluation of Drugs for the Treatment of Congestive Heart Failure (I)12/1/1987Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics6/16/2011Clinical Trial Sponsors on the
Establishment and Operation of Clinical Trial Data Monitoring Committees (I)11/20/2001Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination12/14/2010Combination Products Timeliness of Premarket Reviews (I)5/4/2004Computerized Systems Used in
Clinical Trials (I)10/4/2004Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations2/109/2012Developing Products for Weight Management Revision 1 (I)2/15/2007Development of Parathyroid Hormone for the Prevention
and Treatment of Osteoporosis (I)6/14/2000Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (I)3/3/2008Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals9/12/2002Estrogen and Estrogen/
Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation (I)1/31/2003Exercise-Induced Bronchospasm (EIB) - Development of Drugs to Prevent EIB (I)2/20/2002Gingivitis: Development and Evaluation of
Drugs for Treatment or Prevention (I)6/28/2005Inhalation Drug Products Packaged in Semipermeable Container Closure Systems (I)7/26/2002Investigational New Drug Applications (INDs)-Determining Whether Human Research Studies Can Be Conducted Without an IND
(I)10/14/2010Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs2/14/2012Malaria: Developing Drug and Nonvaccine Biological Products for Treatment and Prophylaxis (I)6/7/2007OTC Treatment of Herpes Labialis with Antiviral Agents
(I)3/8/2000Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval5/30/2012Pediatric Oncology Studies in Response to a Written Request (I)6/21/2000Preparation of IND Applications for New
Drugs Intended for the Treatment of HIV-Infected Individuals9/1/1991Qualification Process for Drug Development Tools (I)10/25/2010Recommendations for Complying with the Pediatric Rule (I)12/4/2000Sinusitis: Designing Clinical Development Programs of Nonantimicrobial Drugs for
Treatment (I)11/22/2006Standards for Clinical Trial Imaging Endpoints8/18/2011Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials8/15/2012The Use of Clinical Holds Following Clinical Investigator Misconduct (I)9/2/2004Clinical PharmacologyIssued
DateDrug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (I)4/7/1997Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications (I)5/6/2003Format and Content of the Human Pharmacokinetics and Bioavailability
Section of an Application (I)2/1/1987In Vivo Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling (I)11/24/1999Pharmacogenomic Data Submissions3/23/2005Pharmacokinetics in Patients With Impaired Hepatic Function;
Study Design, Data Analysis, and Impact on Dosing and Labeling (I)5/30/2003Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling (I)5/15/1998Population Pharmacokinetics (I)2/10/1999Clinical Pharmacology
DraftIssued DateClinical Lactation Studies - Study Design, Data Analysis and Recommendations for Labeling2/8/2005Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies2/18/2011Drug Interaction Studies--Study Design, Data Analysis, Implications for
Dosing, and Labeling Recommendations 2/21/2012 General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products (I) Pharmacokinetics in Pregnancy - Study Design, Data Analysis, and Impact on Dosing and Labeling (I) 11/1/2004 CMC Microbiology Issued
DateSubmission Documentation for Sterilization Process Validation Applications for Human and Veterinary Drug Products (I)11/1/1994CMC Microbiology DraftIssued DateSubmission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products
Terminally Sterilized by Moist Heat Processes (I)8/5/2008Combination Products (Drug/Device/Biologic)Issued DateApplication User Fees for Combination Products (Drug/Device/Biologic) DraftIssued DateCombination Products Timeliness of Premarket
Reviews; Dispute Resolution (I)5/4/2004Coronary Drug-Eluting Stents-Nonclinical and Clinical Studies (I)3/27/2008Current Good Manufacturing Practices/ComplianceIssued DateA Review of FDA's Implementation of the Drug Export Amendments of 1986 (I)5/1/1990Bar Code Label
Requirements - Questions and Answers (Revised) (I)10/5/2006Compressed Medical Gases (I)12/1/1989Computerized Systems Used in Clinical Trials (I)5/10/1999Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigational Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing Practice for Phase 1 Investigation Drugs (I)7/15/2008Current Good Manufacturing 
Positron Emission Tomography Drug Products (I)12/10/2009Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products5/5/2011Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron (I)6/27/1997Formal Dispute Resolution: Scientific and
Technical Issues Related to Pharmaceutical Current Good Manufacturing Practices (I)1/12/2006General Principles of Process Validation (I)5/1/1987Good Laboratory Practice Regulations -- Questions and Answers (I)6/1/1981Guidance for Hospitals, Nursing Homes, and Other Health Care
Facilities (I)4/6/2001 Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production (I)10/12/2006 Marketed Unapproved Drugs; Compliance Policy Guide (I)9/19/2011 Media Fills for Validation of Aseptic Preparations for Positron Emission
Tomography4/11/2012Monitoring of Clinical Investigations (I)1/1/1988Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment (I)5/1/1984Part 11, Electronic Records, Electronic Signatures - Scope and Application9/5/2003PET Drugs — Current Good
Manufacturing Practice (CGMP)8/4/2011Pharmaceutical Components at Risk for Melamine Contamination (I)8/7/2009Pharmacy Compounding --Compliance Policy Guide (I)6/7/2002Possible Dioxin/PCB Contamination of Drug and Biological Products (I)8/23/1999Prescription Drug
Marketing Act Regulations for Donation of Prescription Drug Samples to Free Clinics (I)3/14/2006Process Analytical Technology -- A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance (I)10/4/2004Process Validation: General Principles and
Practices 1/25/2011 Pyrogen and Endotoxins Testing: Questions and Answers 6/28/2012 Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations (I) 10/2/2006 Sterile Drug Products Produced by Aseptic Processing (I) 10/4/2004 Street Drug Alternatives
(I)4/3/2000Testing of Glycerin for Diethylene Glycol (I)5/2/2007The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 - Good Manufacturing Practice (CGMP) (I)1/27/2010Current Good Manufacturing Practices/Compliance DraftIssued DateComparability Protocols -- Protein
Drug Products and Biological Products -- Chemistry, Manufacturing, and Controls Information (1)9/5/2003Current Good Manufacturing Practices for Combination Products (1)10/4/2004Current Good Manufacturing Practices for Medical Gases (3rd Revision) (1)5/6/2003Expiration Dating of
Unit-Dose Repackaged Drugs: Compliance Policy Guide5/31/2005Guidance for IRBs, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research (I)5/12/2000Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Drug and Medical Device Use: Monitoring
Quality2/13/2012Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting, Availability (I)7/14/2009Manufacturing, Processing or Holding of Active Pharmaceutical Ingredients (I)4/17/1998Powder Blends and Finished Dosage Units--
Stratified In-Process Dosage Unit Sampling and Assessment (I)11/7/2003Repackaging of Solid Oral Dosage Form Drug Products2/1/1992Drug Safety Information--Food and Drug Administration's Communication to the Public (I)3/7/2007Drug-Induced Liver Injury:
Premarketing Clinical Evaluation (I)7/30/2009Medication Guides--Distribution Requirements and Inclusion of Medication Strategies 11/17/2011Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an
Influenza Pandemic2/24/2012Postmarketing Studies and Clinical Trials--Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act4/1/2011Drug Safety DraftIssued DateBest Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using
Electronic Healthcare Data Sets2/16/2011Classifying Significant Posmarketing Drug Safety Issues3/9/2012Drug Safety Information -- FDA's Communication to the Public3/9/2012Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and
Proposed REMS Modifications (1)10/1/2009Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act4/13/2011Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies
(I)9/29/2010 Electronic Submissions in Electronic Format - ANDAs (I)6/27/2002 Providing Regulatory Submissions in Electronic Format -- Content of Labeling (I)4/21/2005 Providing Regulatory
Submissions in Electronic Format -- Human Pharmaceutical Product Applications and Related Submissions (I)10/19/2005Regulatory Submissions in Electronic Format; NDAs (I)1/28/1999SPL Standard for
Content of Labeling Technical Qs & As (I)10/28/2009 Electronic Submissions DraftIssued DateCompliance Policy on Reporting Drug Sample Distribution Information Providing Regulatory Submissions in Electronic Format -- Annual Reports for New Drug Applications and Abbreviated
New Drug Applications (I)8/28/2003Providing Regulatory Submissions in Electronic Format--General Considerations (I)10/22/2003Providing Regulatory Submissions in Electronic Format - Postmarketing Expedited Safety Reports (I)5/4/2001Providing Regulatory Submissions in Electronic
Format - Postmarketing Individual Case Safety Reports (I)6/12/2008Providing Regulatory Submissions in Electronic Format - Postmarketing Periodic Adverse Drug Experience Reports (I)6/24/2003Providing Regulatory Submissions in Electronic Format - Prescription Drug Advertising and
Promotional Labeling (I)1/31/2001Providing Regulatory Submissions in Electronic Format -- Standardized Study Data2/21/2012Generic DrugIssued Date180-Day Exclusivity When Multiple Abbreviated New Drug
Applications Are Submitted on the Same Day (I)8/1/2003Abbreviated New Drug Applications: Impurities in Drug Products11/29/2010Alternate Source of Active Pharmaceutical Ingredients in Pending ANDAs (I)12/12/2000ANDAs: Impurities in Drug Substances; Chemistry, Manufacturing and
Controls Information (I)7/15/2009ANDAs: Pharmaceutical Solid Polymorphism; Chemistry, Manufacturing and Controls Information (I)7/9/2007Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act
(I)3/30/2000Handling and Retention of Bioavailability and Bioequivalence Testing Samples (I)5/26/2004Individual Product Bioequivalence Recommendations - List of Product Bioequivalence Recommendations (I)6/11/2010Letter announcing that the OGD will now accept the ICH long-term
storage conditions as well as the stability studies conducted in the past (I)8/18/1995Letter describing efforts by the CDER & the ORA to clarify the responsibilities of CDER chemistry review scientists and ORA field investigators in the new & abbreviated drug approval process in order to
reduce duplication or redundancy in the process (I)10/14/1994Letter on incomplete Abbreviated Applications, Convictions Under GDEA, Multiple Supplements, Annual Reports for Bulk Antibiotics, Batch Size for Transdermal Drugs, Bioequivalence Protocols, Research, Deviations from OGD
Policy (I)4/8/1994Letter on the provision of new information pertaining to new bioequivalence guidelines and refuse-to-file letters (I)7/1/1992Letter on the provision of new procedures and policies affecting the generic drug review process (I)3/15/1989Letter on the request for cooperation of
regulated industry to improve the efficiency and effectiveness of the generic drug review process, by assuring the completeness and accuracy of required information and data submissions (I)11/8/1991Letter on the response to 12/20/84 letter from the Pharmaceutical Manufacturers
Association about the Drug Price Competition and Patent Term Restoration Act (I)3/26/1985Letter to all ANDA and AADA applicants about the Generic Drug Enforcement Act of 1992 (GDEA), and the Office of Generic Drugs intention to refuse-to-file incomplete submissions as required by
```

Abbroughted New Drug Applications (N19/91/9001 Detection Chloride Medi	•	ng, scale-up, packaging, minor/major amendment criteria, and bioequivalence requirer	
	·	ce and In Vitro Dissolution Testing (I)10/26/2005Revising ANDA Labeling Following Res ANDA (I)1/27/1999Generic Drug DraftIssued DateListed Drugs, 30-Month Stays, and	<del>-</del> • • • • • • • • • • • • • • • • • • •
	· · · · · · · · · · · · · · · · · · ·	Generic Drug User Fee Amendments of 2012: Questions and Answers8/27/2012Self- od Review Management Principles for Prescription Drug User Fee Act Products (I)3/3:	<u> </u>
EfficacyIssued DateE1A - The Extent of Population Exposure to Assess Cli	nical Safety: for Drugs Intended for Long Term Treatmen	t of Non-Life-Threatening Conditions (I)3/1/1995E2A - Clinical Safety Data Manageme	nt: Definitions and Standards for Expedited Reporting (I)3/1/1995E2B -
2) (I)3/9/2005E2C - Clinical Safety Data Management: Periodic Safety Upd	ate Reports for Marketed Drugs (I)5/19/1997E2C Addend	lal Case Safety Reports (Revised) (I)4/3/2002E2B(M): Data Elements for Transmission dum - Clinical Safety Data Management: Periodic Safety Update Reports for Marketed	Drugs (I)2/5/2004E2E - Pharmacovigilance Planning (I)4/1/2005E2F
		nse Information to Support Drug Registration (I)11/9/1994E5 - Ethnic Factors in the Ac 9/1997E7 - Studies in Support of Special Populations: Geriatrics (I)8/2/1994E7 Studies	
Answers2/21/2012E8 - General Considerations for Clinical Trials (I)12/24/1	997E9 - Statistical Principles for Clinical Trials (I)9/16/199	98E10 - Choice of Control Group and Related Issues in Clinical Trials (I)5/14/2001E11 10/20/2005E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic	- Clinical Investigation of Medicinal Products in the Pediatric Population
Pharmacogenomics Definitions and Sample Coding (I)4/8/2008E16 Biomar	kers Related to Drug or Biotechnology Product Developm	nent: Context, Structure, and Format of Qualification Submissions8/10/2011ICH - Joint	Safety/Efficacy (Multidisciplinary)Issued DateCompanion Document for
	·	cification (eCTD) (I)4/2/2003M3 - Nonclinical Safety Studies for the Conduct of Human nical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorizat	· · · · · · · · · · · · · · · · · · ·
<del>_</del>	• • • • • • • • • • • • • • • • • • • •	ization of the Common Technical Document (CTD) (I)10/16/2001M4 - The CTD Effic 4M4 - The CTD Safety Questions and Answers (I)2/4/2003ICH - QualityIssued Date	
for Cumene According to the Maintenance Procedures for Q3C Impurities:	Residual Solvents2/23/2012Q10 Pharmaceutical Quality	System (I)4/8/2009Q1A(R2) - Stability Testing of New Drug Substances and Products	(I)11/21/2003Q1B - Photostability Testing of New Drug Substances and
(I)3/1/1995Q2B - Validation of Analytical Procedures: Methodology (I)5/9/19	997Q3A(R) - Impurities in New Drug Substances (I)6/6/20	Testing of New Drug Substances and Products (I)1/16/2003Q1E - Evaluation of Stab 008Q3B(R) - Impurities in New Drug Products (I)7/31/2006Q3C - Impurities: Residual S	Solvents (I)12/24/1997Q3C - Tables and Lists (Revised)
	•	ommendation of Pharmacopoeial Texts for Use in the ICH Regions -Annex 8: Sterility arations General Chapter (I)1/9/2009Q4B Evaluation and Recommendation of Pharma	· · · · · · · · · · · · · · · · · · ·
Particulate Contamination: Subvisible Particles General Chapter (I)1/9/2009	9Q4B Evaluation and Recommendation of Pharmacopoei	ial Texts for Use in the ICH Regions; Annex 4A: Microbiological Examination of Non-Si Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Cha	erile Products: Microbial Enumeration Tests General Chapter
Pharmacopoeial Texts for Use in the ICH Regions-Annex 5: Disintegration	Test General Chapter (I)12/23/2009Q4B Evaluation and I	Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 7(R2) D	issolution Test General Chapter6/23/2011Q4B Evaluation and
·	• • • • • • • • • • • • • • • • • • • •	Electrophoresis General Chapter (I)9/3/2010Q4B Evaluation and Recommendation of macopoeial Texts; Annex 4C: Microbiological Examination of Non-Sterile Products: Acc	·
1 (7		B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the Internation chnology Products: Analysis of the Expression Construct in Cells Used for Production	
Biotechnological Products: Stability Testing of Biotechnology/Biological Pro	ducts (I)7/10/1996Q5D - Quality of Biotechnological/Biolo	ogical Products: Derivation and Characterization of Cell Substrates Used for Production	n of Biotechnological/Biological Products (I)9/21/1998Q5E -
Procedures and Acceptance Criteria for Biotechnological/Biological Produc	ts (I)8/18/1999Q7A - Good Manufacturing Practice for Ac	cations: Test Procedures and Acceptance Criteria for New Drug Substances and New tive Pharmaceutical Ingredients (I)9/25/2001Q8 (R2) - Pharmaceutical Development (I	)11/19/2009Q8, Q9, and Q10 Questions and Answers (I)11/1/2011ICH
		- Quality Risk Management (I)6/2/2006ICH - SafetyIssued DateS1A - The Need for Lo armaceuticals (I)3/1/1995S1C(R2) - Dose Selection for Carcinogenicity Studies of Pha	
(I)9/17/2008S2A - Specific Aspects of Regulatory Genotoxicity Tests for Ph	armaceuticals (I)4/24/1996S2B - Genotoxicity: Standard	Battery Testing (I)11/21/1997S2(R1) Genotoxicity Testing and Data Interpretation for F Studies (I)3/1/1995S4A - Duration of Chronic Toxicity Testing in Animals (Rodent and N	Pharmaceuticals Intended for Human Use6/7/2012S3A - Toxicokinetics:
Reproduction for Medicinal Products (I)9/22/1994S5B - Detection of Toxicit	y to Reproduction for Medicinal Products: Addendum on	Toxicity to Male Fertility (I)4/5/1996S6(R1) Preclinical Safety Evaluation of Biotechnolo	gy-Derived Pharmaceuticals5/18/2012S7A - Safety Pharmacology
EfficacyIssued DateE12A Principles for Clinical Evaluation of New Antihype	ertensive Drugs (I)8/9/2000E2B(R) - Clinical Safety Data I	(QT Interval Prolongation) by Human Pharmaceuticals (I)10/20/2005S8 - Immunotoxion Management: Data Elements for Transmission of Individual Case Safety Reports (I)10	/3/2005E2B(R3) Electronic Transmission of Individual Case Safety
· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	ards and Forwards Compatibility10/19/2011E2C(R2) Periodic Benefit-Risk Evaluation Frata Elements and Standards for Drug Dictionaries (I)Submitting Marketing Application	· · · · · · · · · · · · · · · · · · ·
Draft - QualityIssued DateICH Q3C Maintenance Procedures for the Guida	nce for Industry Q3C Impurities: Residual Solvents - Draf	t Recommendation for the Revision of the Permitted Daily Exposure for Cumene (I)7/2	0/2010Q4B Evaluation and Recommendation of Pharmacopoeial Texts
and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions	s -Annex 6: Uniformity of Dosage Units General Chapter (	and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions -Annex 14: (I)2/17/2009Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in	the ICH Regions-Annex 9: Tablet Friability General Chapter
	· · · · · · · · · · · · · · · · · · ·	Gel Electrophoresis General Chapter (I)8/14/2009Q11 Development and Manufacture or Anticancer Pharmaceuticals (I)2/17/2009INDsIssued DateContent and Format of IN	
Therapeutic, Biotechnology-Derived Products (I)10/4/2000Industry Letters!	ssued DateA Revision in Sample Collection Under the Co	ompliance Program Pertaining to Pre-Approval Inspections7/15/1996Certification Requ	irements for Debarred Individuals in Drug
informal notice about the Act, discussing the statutory mechanism by which	ANDA applicants may make modifications in approved o	bility of Policy and Procedure Guides, and further operational changes to the generic of drugs where clinical data is required (I)4/10/1987Fourth of a series of letters providing i	nformal notice to all affected parties about policy developments and
, , , , , , , , , , , , , , , , , , , ,		ion and Patent Term Restoration Act. Preliminary Guidance (I)10/11/1984Implementat 30-day exclusivity" provision of section 505(j)(4)(B)(iv) of the FD&C (I)7/29/1988Sixth o	, , , , , , , , , , , , , , , , , , , ,
	· · · · · · · · · · · · · · · · · · ·	Supplement to 10/11/84 letter about policies, procedures and implementation of the Ac ns Section of Labeling for Human Prescription Drug and Biological Products; Content a	
Labeling3/1/1981Clinical Studies Section of Labeling for Human Prescription	on Drug and Biological Products; Content and Format (I)1	/24/2006Content and Format for Geriatric Labeling (I)10/5/2001Hypoglycemic Oral Ag	ents - Federal Register4/1/1984Hypertension Indication: Drug Labeling
Labeling In Reference Listed Drugs and Abbreviated New Drug Application	s (I)10/18/2002Local Anesthetics - Class Labeling9/1/198	ed Pharmacologic Class for Use in the Highlights of Prescribing Information (I)10/19/2 32Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug	Produts and Antimicrobial Susceptibility Testing Devices
	•	I Biological Products - Content and Format (I)10/11/2011Labeling DraftIssued DateClir Human Prescription Drug and Biological Products (I)4/9/2007Contents of a Complete S	
(I)11/24/2008Labeling for Combined Oral Contraceptives (I)3/5/2004Labelin	ng for Human Prescripstion Drug and Biological Products	- Implementing the New Content and Format Requirements (I)1/24/2006Noncontrace ng (I)11/16/2005Public Availability of Labeling Changes in "Changes Being Effected" S	otive Estrogen Drug Products for the Treatment of Vasomotor Symptoms
Drugs in Abbreviated New Drug Applications (I)10/26/2000Modernization A	ctIssued DateChanges to an Approved NDA or ANDA4/2	2004Classifying Resubmissions in Response to Action Letters 5/14/1998Fast Track Dr	ug Development Programs - Designation, Development, and Application
	•	and Applicants for PDUFA Products5/19/2009Implementation of Section 120 of the Fo Dertain Labeling Requirements7/1998Information Program on Clinical Trials for Serious	
	<u> </u>	Biological Products5/14/1998Qualifying for Pediatric Exclusivity Under Section 505A of Exclusivity (505A), The Pediatric "Rule," and Their Interaction7/27/1999Reports on the contraction of the contractio	
<u> </u>	·	, , , , , , , , , , , , , , , , , , , ,	Marketing Applications8/1998Submitting and Reviewing Complete
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food,	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format ( Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Coun Answers Regarding the Labeling of Nonprescription Human Drug Products	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 2010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2012	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required sification of Benzoyl Peroxide as Safe and Effective; Sma ferrals (I)12/19/2000Organ-Specific Warnings: Internal An	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2011 Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego algesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Userspirants	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counted Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required sification of Benzoyl Peroxide as Safe and Effective; Sma ferrals (I)12/19/2000Organ-Specific Warnings: Internal And on Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, ELabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 2010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2011 Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Categoralgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Userharmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (I)5/2011 Clinical Pharmacology/Toxicology Section of an Application (I)2/1/1987Immunotoxicology	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical ogy Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preventions	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Ferrals (I)12/19/2000Organ-Specific Warnings: Internal And In On Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None It the Transmission of Sexually Transmitted Diseases (ST	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 2010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 all Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Categoralgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Pharmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (I)5/2 clinical Pharmacology/ Toxicology Section of an Application (I)2/1/1987Immunotoxicology) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (I)10/2	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug ry I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical ogy Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical L6/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic
Responses to Clinical Holds10/2000Modernization Act Draftlssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E(I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology	ormation Program on Clinical Trials for Serious or Life-The Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small terrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None at the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Nonclinical Safety Evant Study Results (I)1/4	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Blabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 2010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2011 Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Categoralgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Pharmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (I)5/2011 Clinical Pharmacology/Toxicology Section of an Application (I)2/1/1987Immunotoxicology) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (I)10/2014 Cluation of Pediatric Drug Products (I)2/15/2006Nonclinical Studies for the Safety Evaluation Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies for Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies for Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies for Antiviral Drugs Indicated for the Treatment of N/A Non-Life Telephone Toxicity Studies for the Safety Evaluation of Pediatric Drugs Indicated for the Treatment of N/A Non-Life Telephone Te	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical Drag Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical L6/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfo Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counted Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani	ormation Program on Clinical Trials for Serious or Life-The Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Internals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None at the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evaluation Study Results (I)1/4/2006Reference Guide for the Nonclinical Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impuri	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, ELabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 2010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 all Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego algesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Userharmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (I)5/2 clinical Pharmacology/ Toxicology Section of an Application (I)2/1/1987Immunotoxicology) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (I)10/2 clinical Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Tiesting of Drug Metabolites (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacolities in Drug Substances and Products: Recommended Approaches (I)12/16/2008None	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical L6/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical Euticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued Clinical Safety Evaluation of Reformulated Drug Products and Products
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInformation OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp	ormation Program on Clinical Trials for Serious or Life-The Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Ferrals (I)12/19/2000Organ-Specific Warnings: Internal Annon Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None of the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Noncley Study Results to Assess Concerns9/22/2011Safety Test and Rule (I)1/21/2009Genotoxic and Carcinogenic Impurioects of the Design, Analysis, and Interpretation of Chronical Safety Formal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurioects of the Design, Analysis, and Interpretation of Chronical Safety Evant Rule (I)1/21/2009Genotoxic and Carcinogenic Impurioects of the Design, Analysis, and Interpretation of Chronical Safety Evant Rule (I)1/21/2009Genotoxic and Interpretation of Chronical Safety Eva	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product 1010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2011 Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Categoralgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Usermacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (I)5/2011 Pharmacology/Toxicology Section of an Application (I)2/1/1987Immunotoxicology) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (I)10/2012 Products (I)2/15/2006Nonclinical Studies for the Safety Evaluation of Pediatric Drug Products (I)2/15/2006Nonclinical Studies for the Safety Evaluation of Drug Metabolites (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting of Drug Metabolites (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting Category Toxicology Studies (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting of Drug Metabolites (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting Category III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting of Drug Metabolites (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacesting III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing III Antiperspirate Products (I)2/15/2008Single Dose Acute Toxicity Testing III Antiperspirate Products (	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical Evaluation Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInfold Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Count Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E(I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under Intended Statistics (I)2/1/1989Reproductive Intended Statistics (I)2/	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Ferrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None of the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Noncle of Study Results to Assess Concerns9/22/2011Safety Test mal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurious of the Design, Analysis, and Interpretation of Chronical Compounding of Tamiflu Oral Suspension to Provide the Hatch-Waxman Amendments to the Federal Fooder	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Blabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (I)1000000000000000000000000000000000000	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug and I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical L6/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic action of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical euticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Count Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Add Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Un Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application In	ormation Program on Clinical Trials for Serious or Life-The Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Liter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Ferrals (I)12/19/2000Organ-Specific Warnings: Internal Annon Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None of the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evant Study Results (I)1/4/2006Reference Guide for the Noncle of Study Results to Assess Concerns9/22/2011Safety Test and Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity Dects of the Design, Analysis, and Interpretation of Chronic vance Compounding of Tamiflu Oral Suspension to Provide the Hatch-Waxman Amendments to the Federal Food anuary 1, 2000 (I)11/30/1999Drug Products Containing EReview (I)11/18/1998FDA Export Certificate (I)7/12/2004F	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Blabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Categoral (II) Entity Country Country Country Country Country Country Country Country Control (II) (II) (II) (II) (II) (II) (II) (II	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug et al. (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical et al. (A)1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic action of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical euticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Count Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Un Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Ferrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncombinations (I)3/15/2006Nonclinical Safety Evaluated Results (I)1/4/2006Reference Guide for the Noncombinations (I)3/15/2006Nonclinical Safety Testing Study Results to Assess Concerns9/22/2011Safety Testing Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity and Compounding of Tamiflu Oral Suspension to Province the Hatch-Waxman Amendments to the Federal Foodenaury 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004Formization Act of 1997 - Elimination of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Tamiflu Oral Suspension Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004Formization Act of 1997 - Elimination of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results (I)3/7/2000Formal Meetings Between the FDA and Spontance Compounding Of Suspension Of Certain Labeling Results	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (I)10Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (I)10Postmarketing Adverse Event Reporting Category III Antiperspirants to Catego (I)10Postmarketing (I)1	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ets; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical Evaluation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical entiticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling extening Diseases and Conditions (I)3/18/2002Integrated Summaries of
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Un Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Document	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Products (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncombination of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evalus (Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity and Products of the Design, Analysis, and Interpretation of Chronic Vance Compounding of Tamiflu Oral Suspension to Provide the Hatch-Waxman Amendments to the Federal Food anuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004F (I)3/7/2000Formal Meetings Between the FDA and Spontantial Certain Act of 1997 - Elimination of Certain Labeling Report (I)4/21/2009Levothyroxine Sodium Products - Enforcer	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (1010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Category III Antiperspiran	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ats; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug and Italian and Extent Applications (I)9/28/2011Topical Acne Drug and Italian Ital
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E(I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Unconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Docume Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs In Injection8/31/2011PET Drug Applications - Content and Format for NDAs a	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Perrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the None It the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evally Study Results (I)1/4/2006Reference Guide for the Noncle Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity Products of the Design, Analysis, and Interpretation of Chronical Vance Compounding of Tamiflu Oral Suspension to Proving the Hatch-Waxman Amendments to the Federal Foolanuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004F(I)3/7/2000Formal Meetings Between the FDA and Spont (I)3/7/2000Formal Meetings Between the FDA and Spont (I)3/7/2009Levothyroxine Sodium Products - Enforcern (I)4/21/2009Levothyroxine Sodium Products - Enforcern (I)4/21/2009Levothyroxine Sodium Products - Enforcern (I)4/21/2098Levothyroxine Sodium Products - Enforcern (I)4/21/2009Levothyroxine Sodium Products - Enforcern (I)4/21/2009L	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Elabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (I)1000000000000000000000000000000000000	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs sts; Questions and Answers1/5/2009Organ-Specific Warnings: Internal s Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug ry I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling se — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical agy Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical L6/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical cuticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV dministration Modernization Act of 1997- Elimination of Certain Labeling extening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 Figh Absenteeism to Ensure Availability of Medically Necessary Drug
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cound Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Preven Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E(I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Unconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs In Injection8/31/2011Pet Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section	ormation Program on Clinical Trials for Serious or Life-The Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Smalerrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncomplete the Transmission of Sexually Transmitted Diseases (STabiologic Combinations (I)3/15/2006Nonclinical Safety Evanty Study Results (I)1/4/2006Reference Guide for the Noncomplete (I)1/21/2009Genotoxic and Carcinogenic Impurity and Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity and Compounding of Tamiflu Oral Suspension to Provided the Hatch-Waxman Amendments to the Federal Foodmanuary 1, 2000 (I)11/30/1999Drug Products Containing Effective (I)1/12/2004Formal Meetings Between the FDA and Sponternization Act of 1997 - Elimination of Certain Labeling Report (I)3/7/2009Levothyroxine Sodium Products - Enforcemparedient Labeling for OTC Drugs (I)4/9/1998PET Drug Aund ANDAs: Attachment I: Sample formats for chemistry, Incompany 1, 2000 (I)12/23/2002Potassium Iodide as a The 505A of the Federal Food, Drug, and Cosmetic Act - Reviews (I)12/23/2002Potassium Iodide as a The 505A of the Federal Food, Drug, and Cosmetic Act - Reviews (I)19/19/1998PET Drug Aund ANDAs: Attachment I: Sample formats for chemistry, Incompany Inc	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Elabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (I)10Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (II) Entity Compliance Oracle Study Protocol Submissions (I)5/2011 Entity Category Protocol Submissions (II)5/2011/1987Immunotoxicologory Compliance of Pediatric Drug Products (I)2/15/2006Nonclinical Studies for the Safety Evalutional Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Theologory Compliance of Mategory Category III Antiperspirance (I)12/16/2008Nonclinical Toxicity Studies of Pharmaceuticals (I)5/8/2001ProceduralIssued Date of Multiple Prescriptions (I)12/29/2009Citizen Petitions and Petitions for Stay of Active Compliance Active Compliance Octinoxate, and Octisalate - Labeling Enforcemental Disclosure by Clinical Investigators (I)3/28/2001Fixed Dose Combinations and Petitions and Products (I)1/1/1998Information Program on Clinical Trials for Serious or Life-Threment of August 14, 2001, Compliance Date and Submission of New Applications (I)7/12/19p8Information Program on Clinical Trials for Serious or Life-Threment of August 14, 2001, Compliance Date and Submission of New A	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ats; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug and It (13 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling and Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical Ed/1996Nonclinical Exclusional New Drugs (I)11/1/2002Nonclinical Ed/1996Nonclinical Excipients5/19/2005Photosafety Testing areatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical acticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling extening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 High Absenteeism to Ensure Availability of Medically Necessary Drug as Shelf Life Extension for Federal Agencies and State and Local d, Drug, and Cosmetic Act (I)6/15/1998Reports on the Status of
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cound Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Urconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011Pet Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small errals (I)12/19/2000Organ-Specific Warnings: Internal Anon Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncombinations (I)3/15/2006Nonclinical Safety Evalve Study Results (I)1/4/2006Reference Guide for the Noncombinations of the Design, Analysis, and Interpretation of Chronic Products of the Design, Analysis, and Interpretation of Chronic Products of the Design, Analysis, and Interpretation of Chronic Products (I)1/18/1998FDA Export Certificate (I)7/12/2004F (I)3/7/2000Formal Meetings Between the FDA and Spontant (I)1/21/2009Levothyroxine Sodium Products - Enforcer Ingredient Labeling for OTC Drugs (I)4/9/1998PET Drug And ANDAs: Attachment I: Sample formats for chemistry, Incoms and Answers (I)12/23/2002Potassium Iodide as a The 505A of the Federal Food, Drug, and Cosmetic Act - Review Gadministration Modernization Act of 1997 (I)2/16/2006 (I)2/16/2006 (I)2/16/2006 (I)2/26/2000The Leveraging Handbook; and Cosmetic Act - Review Gadministration Modernization Act of 1997 (I)2/16/2006 (I)2/16/2006 (I)2/26/2000The Leveraging Handbook; and Cosmetic Act - Review Gadministration Modernization Act of 1997 (I)2/16/2006 (I)2/26/2000The Leveraging Handbook; and Cosmetic Act - Review Gadministration Modernization Act of 1997 (I)2/16/2006 (I)2/26/2000The Leveraging Handbook; and Cosmetic Act - Review Gadministration Modernization Act of 1997 (I)2/16/2006 (I)2/2006 (I)2/2006 (I)2/2000The Leveraging Handbook; and Cosmetic Act - Review Gadministration Act of 1997 (I)2/16/2006 (I)2/2006 (I)2/20	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Elabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (I)10/10/2011Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance) (III Entity Protocol Submissions (I)5/10/10/10/10/10/10/10/10/10/10/10/10/10/	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs atts; Questions and Answers1/5/2009Organ-Specific Warnings: Internal and Rarketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical Ed/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic attion of Pharmaceutical Excipients5/19/2005Photosafety Testing areatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical exticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products atte180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling eatening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 Fligh Absenteeism to Ensure Availability of Medically Necessary Drug as Shelf Life Extension for Federal Agencies and State and Local Approach and Cosmetic Act (I)6/15/1998Reports on the Status of Applements, Including Priority Efficacy Supplements Foll-Free Number Labeling and Related Requirements for Over-the-
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cound Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E(I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Urconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011PET Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drug	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small Entity (I)12/19/2000Organ-Specific Warnings: Internal Anon Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncit the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evally Study Results (I)1/4/2006Reference Guide for the Noncit general Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity and Compounding of Tamiflu Oral Suspension to Provider the Hatch-Waxman Amendments to the Federal Food anuary 1, 2000 (I)11/30/1999Drug Products Containing Exercise (I)1/18/1998FDA Export Certificate (I)7/12/2004F (I)3/7/2000Formal Meetings Between the FDA and Spontant (I)4/21/2009Levothyroxine Sodium Products - Enforcer Ingredient Labeling for OTC Drugs (I)4/9/1998PET Drug And ANDAs: Attachment I: Sample formats for chemistry, Italian and Answers (I)12/23/2002Potassium Iodide as a The 505A of the Federal Food, Drug, and Cosmetic Act - Reviug Administration Modernization Act of 1997 (I)2/16/2006 (I)2/16/2000 (I)10/26/2000The Leveraging Handbook; and Entity Compliance Guide6/15/2012Useful Written Contain and Intity Co	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Elabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (I)10/10/2001Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Categor (III Entity Country Category Cate	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ats; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (1)7/14/2009Questions and 2009Time and Extent Applications (1)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (1)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (1)11/1/2002Nonclinical Ed/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing areatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical euticals - Revised (1)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products atte180-Day Generic Drug Exclusivity Under the Hatch-Waxman and Exception Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (1)6/3/2003End-of-Phase 2A Meetings (1)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling eatening Diseases and Conditions (1)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 Fligh Absenteeism to Ensure Availability of Medically Necessary Drug as Shelf Life Extension for Federal Agencies and State and Local Applications, Including Priority Efficacy Supplements Foll-Free Number Labeling and Related Requirements for Over-the-quirements7/20/1998Procedural DraftIssued DateApplications Covered
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Coun Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E(I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp. Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Ad Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Ur Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)1/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011Pet Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs M	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small terrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Nonch the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evalus of Study Results (I)1/4/2006Reference Guide for the Nonch of Study Results (I)1/4/2006Reference Guide for the Nonch of Study Results (I)1/4/2006Reference Guide for the Nonch of Study Results of Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity Products of the Design, Analysis, and Interpretation of Chronic Vance Compounding of Tamiflu Oral Suspension to Provide the Hatch-Waxman Amendments to the Federal Food anuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004 (I)3/7/2000Formal Meetings Between the FDA and Spontantiation Act of 1997 - Elimination of Certain Labeling Report Certai	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Blabel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 lll Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (Ill Entity Compliance III) Indicated Data (Ill Protocol Submissions (Ill) (Ill Category Indicated Protocol Submissions (Ill Category Indicated Indica	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs tes; Questions and Answers1/5/2009Organ-Specific Warnings: Internal and Samaketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug (I)9 I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling as — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical and Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical auticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling extening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18  High Absenteeism to Ensure Availability of Medically Necessary Drug as Shelf Life Extension for Federal Agencies and State and Local d. Drug, and Cosmetic Act (I)6/15/1998Reports on the Status of Act Supplements, Including Priority Efficacy Supplements  Toll-Free Number Labeling and Related Requirements for Over-the-quirements 1/20/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisory Committees in Co
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cound Answers Regarding the Labeling of Nonprescription Human Drug Products Products For Over-the-Counter Human User-Revision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp. Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusiving or J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Document Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Products3/15/2011Potassium lodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs Marketed With Approved Applications in by Section 505(b)(2) (I)12/8/19	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ater Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Smalerrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Nonct the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evaly Results (I)1/4/2006Reference Guide for the Noncley Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity and Compounding of Tamiflu Oral Suspension to Provided the Hatch-Waxman Amendments to the Federal Foodmanuary 1, 2000 (I)11/30/1999Drug Products Containing Effective (I)3/7/2000Formal Meetings Between the FDA and Spontantiation Act of 1997 - Elimination of Certain Labeling Rent (I)4/21/2009Levothyroxine Sodium Products - Enforcern and Andras: Attachment I: Sample formats for chemistry, Indicated (I)1/2/23/2002Potassium Iodide as a Theography of the Federal Food, Drug, and Cosmetic Act - Reviug Administration Modernization Act of 1997 (I)2/16/2006 (I)2/23/2002Potassium Iodide as a Theography of the Federal Food, Drug, and Cosmetic Act - Reviug Administration Modernization Act of 1997 (I)2/16/2006 (I)2/16/2000The Leveraging Handbook; and Entity Compliance Guide6/15/2012Useful Written Confulticenter Clinical Trials3/23/2005Clinical Trial Sponsors uphy Drug Products (I)3/10/2000Dear Healthcare Provider New Drugs and Convened by CDER, Beginning January availability (I)7/5/2005End-of-Phase 2A Meetings (I)9/26/2007	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, it abel Comprehension Studies for Nonprescription Drug Products (1)8/3/2010Labeling Entity Compliance Guide (1)5/13/2009Labeling Over-the-Counter Human Drug Product (0)10Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)9/1/2 (1) Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ats; Questions and Answers1/5/2009Organ-Specific Warnings: Internal stanketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling Set — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical page Evaluation of Investigational New Drugs (I)11/1/2002Nonclinical L6/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical evaluations of Reformulated Drug Products and Products tet180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling teatening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18  High Absenteeism to Ensure Availability of Medically Necessary Drug as Shelf Life Extension for Federal Agencies and State and Local did, Drug, and Cosmetic Act (I)6/15/1998Reports on the Status of y Supplements, Including Priority Efficacy Supplements Toll-Free Number Labeling and Related Requirements for Over-the-quirements7/20/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisory Committees in Connection with yees Participating in FDA Product Specific Advisory
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cound Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998AdAct6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Un Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Docume Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011PET Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs M	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Smalerrals (I)12/19/2000Organ-Specific Warnings: Internal Anon Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Nonct the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Eval Study Results (I)1/4/2006Reference Guide for the Noncl g Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurivance Compounding of Tamiflu Oral Suspension to Providente Hatch-Waxman Amendments to the Federal Foodanuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004f (I)3/7/2000Formal Meetings Between the FDA and Sponsor (I)4/21/2009Levothyroxine Sodium Products - Enforcern (I)4/21/2009Levothyroxine Sodium	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, it abel Comprehension Studies for Nonprescription Drug Products (I)8/3/2010Labeling Entity Compliance Guide (I)5/13/2009Labeling Over-the-Counter Human Drug Product (D10Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (I)9/1/2 II Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego halpesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Pharmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (I)5/2 clinical Pharmacology/ Toxicology Section of an Application (I)2/1/1987Immunotoxicology Dand/or the Development of Drugs Intended to Act as Vaginal Contraceptives (I)10/2 duation of Pediatric Drug Products (I)2/15/2006Nonclinical Studies for the Safety Evaluinical Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Tisting of Drug Metabolites (I)2/15/2008Single Dose Acute Toxicity Testing for Pharmacetities in Drug Substances and Products: Recommended Approaches (I)12/16/2008Noncic Rodent Carcinogenicity Studies of Pharmaceuticals (I)5/8/2001ProceduralIssued Dade for Multiple Prescriptions (I)12/29/2009Citizen Petitions and Petitions for Stay of Acd, Drug, and Cosmetic Act3/27/2000Disclosure of Materials Provided to Advisory Comercian Studies of Pharmaceuticals (I)5/8/2001FroceduralIssued Dade for Multiple Prescriptions (I)12/29/2009Citizen Petitions and Petitions for Stay of Acd, Drug, and Cosmetic Act3/27/2000Disclosure of Materials Provided to Advisory Comercian Disclosure by Clinical Investigators (I)3/28/2001Fixed Dose Combinations and Insors or Applicants (I)5/14/2009Implementation of Section 120 of the Food and Drug Acquirements, (I)7/11/998Information Program on Clinical Trials for Serious or Life-Threment of August 14, 2001, Compliance Date and Submission of New Applications (I)6/19/2003 non-polications — Content and For	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTClssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs its; Questions and Answers1/5/2009Organ-Specific Warnings: Internal its Marketed without an Approved Application ()7/14/2009Questions and 2009Time and Extent Applications ())9/28/2011Topical Acne Drug its (143 FR 46728 - 46731) ())10/10/1978OTC DraftIssued DateLabeling its — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical orgy Evaluation of Investigational New Drugs ())11/1/2002Nonclinical 16/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical euticals - Revised ())8/26/1996Pharmacology/Toxicology DraftIssued Clinical Safety Evaluation of Reformulated Drug Products and Products tet180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy ())6/3/2003End-of-Phase 2A Meetings ())9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling extening Diseases and Conditions ())3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 i High Absenteeism to Ensure Availability of Medically Necessary Drug ss Shelf Life Extension for Federal Agencies and State and Local dr., Drug, and Cosmetic Act (1)6/15/1998Reports on the Status of y Supplements, Including Priority Efficacy Supplements for Over-the-quirements7/20/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisory Committees in Connection with yees Participating i
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Coun Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Ad/Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Unconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Requirements (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011Pct Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs Marketed With Approved Applications' Sm by Section 505(b)(2) (I)12/8/199	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Smalerrals (I)12/19/2000Organ-Specific Warnings: Internal An on Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncott the Transmission of Sexually Transmitted Diseases (ST Stody Results (I)1/4/2006Reference Guide for the Noncott the Stody Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity and the Design, Analysis, and Interpretation of Chronicy and the Hatch-Waxman Amendments to the Federal Foodanuary 1, 2000 (I)11/30/1999Drug Products Containing Exeview (I)11/18/1998FDA Export Certificate (I)7/12/2004Formal Meetings Between the FDA and Spontantian Act of 1997 - Elimination of Certain Labeling Rent (I)4/21/2009Levothyroxine Sodium Products - Enforcemage and Answers (I)12/23/2002Potassium Iodide as a The So55A of the Federal Food, Drug, and Cosmetic Act - Reviug Administration Modernization Act of 1997 (I)2/16/2006 (I)3 (Revised) (I)10/26/2000The Leveraging Handbook; and all Entity Compliance Guide6/15/2012Useful Written Confulticenter Clinical Trials3/23/2005Clinical Trial Sponsors (I)11/25/2005End-of-Phase 2A Meetings (I)9/26/26/2005 (I)9/25/2005End-of-Phase 2A Meetings (I)9/26/26/2005 (I)9/25/2005End-of-Phase 2A Meetings (I)9/26/26/2005 (I)9/26/2005 (I)9/2005 (II)9/2005 (II)9/2005 (II)9/2005 (II)9/2005 (II)9/2	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, itabel Comprehension Studies for Nonprescription Drug Products (1)8/3/2010Labeling Entity Compliance Guide (1)5/13/2009Labeling Over-the-Counter Human Drug Product (010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)9/1/2 ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego lalgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Usinarmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (1)5/10-10-10-10-10-10-10-10-10-10-10-10-10-1	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs its; Questions and Answers1/5/2009Organ-Specific Warnings: Internal its Marketed without an Approved Application (1)7/14/2009Questions and 2009Time and Extent Applications (1)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (1)10/10/1978OTC DraftIssued DateLabeling its — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical Info/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical 20/2016/1996Pharmacology/Toxicology DraftIssued Clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (1)6/3/2003End-of-Phase 2A Meetings (1)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV deministration Modernization Act of 1997- Elimination of Certain Labeling attening Diseases and Conditions (1)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18  High Absenteeism to Ensure Availability of Medically Necessary Drug is Shelf Life Extension for Federal Agencies and State and Local 4, Drug, and Cosmetic Act (1)6/15/1998Reports on the Status of 7 supplements, Including Priority Efficacy Supplements Toll-Free Number Labeling and Related Requirements for Over-the- puirements/120/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisory Committees in Connection with yees Participating in FDA Product Specific Advisory Comme
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Cound Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp. Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Adv. Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Urconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011PET Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Question Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs Marketed With Approved Applications's Sm by Section 505(b)(2) (I)12/	cormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small Iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required infication of Benzoyl Peroxide as Safe and Effective; Small errals (I)12/19/2000Organ-Specific Warnings: Internal Anion Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Nonct the Transmission of Sexually Transmitted Diseases (ST Sciologic Combinations (I)3/15/2006Nonclinical Safety Evalus (I)1/4/2006Reference Guide for the Nonct Study Results (I)1/4/2006Reference Guide for the Nonct Grand Rule (I)1/21/2009Genotoxic and Carcinogenic Impurity Products of the Design, Analysis, and Interpretation of Chronicy and Compounding of Tamiflu Oral Suspension to Provided the Hatch-Waxman Amendments to the Federal Foolanuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004 (I)3/7/2000Formal Meetings Between the FDA and Spont (I)4/21/2009Levothyroxine Sodium Products - Enforcer and Andrew (I)4/21/2009Levothyroxine Sodium Products - Enforcer (I)4/21/2009Levothyroxine Sodium Products - Enforcer (I)4/21/2009Levothyroxine Sodium Products - Enforcer (I)4/21/2009Levothyroxine Sodium Products - Review Administration Modernization Act of 1997 (I)2/16/2006 (I)	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Itabel Comprehension Studies for Nonprescription Drug Products (1)8/3/2010Labeling Entity Compliance Guide (1)5/13/2009Labeling Over-the-Counter Human Drug Product (010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)9/1/2 Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego alagesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Userharmacology/Toxicology/Section of an Application (1)2/1/1987Immunotoxicology Indivorse David Pharmacology/Toxicology Section of an Application (1)2/1/1987Immunotoxicology David/or the Development of Drugs Intended to Act as Vaginal Contraceptives (1)10/10-2016/2008/10	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAS tas; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (1)7/14/2009Questions and 2009Time and Extent Applications (1)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (1)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical page Evaluation of Investigational New Drugs (1)11/1/2002Nonclinical 16/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical evaluations - Revised (1)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (1)6/3/2003End-of-Phase 2A Meetings (1)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling seatening Diseases and Conditions (1)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 i High Absenteeism to Ensure Availability of Medically Necessary Drug s Shelf Life Extension for Federal Agencies and State and Local 4, Drug, and Cosmetic Act (1)6/15/1998Reports on the Status of A Supplements, Including Priority Efficacy Supplements Toll-Free Number Labeling and Related Requirements for Over-the-  puirements7/20/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisor
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Count Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human Use-Revision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp. Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Ach Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Ur Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Effectiveness and Safety: Location Within the Common Technical Documen Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011PET Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs Marketed With Approved Applications" Sm by Section 505(b)(2) (I)12/	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small terrals (I)12/19/2000Organ-Specific Warnings: Internal An on Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Nondat the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evals Study Results (I)1/4/2006Reference Guide for the Noncleg Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impurisects of the Design, Analysis, and Interpretation of Chronical Compounding of Tamiflu Oral Suspension to Provided the Hatch-Waxman Amendments to the Federal Foodanuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004f (I)3/7/2000Formal Meetings Between the FDA and Spondand And Act of 1997 - Elimination of Certain Labeling Report (I)4/21/2009Levothyroxine Sodium Products - Enforcern Orgedient Labeling for OTC Drugs (I)4/9/1998PET Drug And ANDAs: Attachment I: Sample formats for chemistry, Inions and Answers (I)12/23/2002Potassium Iodide as a Thiosos and Answers (I)12/23/2002Potassium Iodide as a Thiosos And Answers (I)12/23/2002Potassium Iodide as a Thiosos And Answers (I)12/23/2002Potassium Iodide Act - Revieug Administration Modernization Act of 1997 (I)2/16/2006 (I)8 (Revised) (I)10/26/2000The Leveraging Handbook; and Entity Compliance Guide6/15/2012Useful Written Confulticenter Clinical Trials3/23/2005Clinical Trial Sponsors uphy Drug Products (I)8/10/2000Dear Healthcare Provided New Drugs and Convened by CDER, Beginning January in Amaliability (I)7/5/2005End-of-Phase 2A Meetings (I)9/26/2007: Gress Guidance for Clinical Investigators, Industry, and FD fire Research Equity Act (I)9/7/2005Ind	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Itabel Comprehension Studies for Nonprescription Drug Products ())8/3/2010Labeling Entity Compliance Guide ())5/13/2009Labeling Over-the-Counter Human Drug Product ()10Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)9/1/2 Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego alagesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Drug harmacology/Toxicology/ssued DateCarcinogenicity Study Protocol Submissions (1)5/5/clinical Pharmacology/ Toxicology Section of an Application (1)2/1/1987Immunotoxicold (1) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (1)10/1/10/1010 (1)2/1019 (1)2/15/2006Nonclinical Studies for the Safety Evaluation of Pediatric Drug Products (1)2/15/2006Nonclinical Studies for the Safety Evaluation of Pediatric Drug Products: Recommended Approaches (1)12/15/2008Nonc is Rodent Carcinogenicity Studies of Pharmaceuticals (1)5/8/2001ProceduralIssued Dade for Multiple Prescriptions (1)12/29/2009Citizen Petitions and Petitions for Stay of Act d., Drug, and Cosmetic Act3/27/2000Disclosure of Materials Provided to Advisory Communical Disclosure by Clinical Investigators (1)3/28/2001Fixed Dose Combinations an Isors or Applicants (1)5/14/2009Implementation of Section 120 of the Food and Drug Acquirements, (1)7/21/1998Information Program on Clinical Trials for Serious or Life-Threnent of August 14, 2001, Compliance Date and Submission of New Applications (1)71/1998Information Emergencies (1)12/10/2001Potassium lodide Tableised (1)10/1/1999Refusal to File (1)7/12/1993Repeal of Section 507 of the Federal Foot Special Protocol Assessment (1)5/17/2002Standards for the Prompt Review of Efficacy on Agency Resource for Effective Collaborations - Guidance for FDA Staff (1)6/19/2003 sumer Medication Information (CMI) (1)7/18/2006Women and Minori	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTClssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ats; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug by I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling is Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical draftion of Investigational New Drugs (I)11/1/2002Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic attion of Pharmaceutical Excipients5/19/2005Photosafety Testing Dreatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical euticals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling patening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 Filigh Absenteeism to Ensure Availability of Medically Necessary Drug s Shelf Life Extension for Federal Agencies and State and Local 1, Drug, and Cosmetic Act (I)6/15/1998Reports on the Status of y Supplements, Including Priority Efficacy Supplements ToVer-the-juirements7/20/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisory Committees in Connection with yees Participating in FDA Product Specific Advisory
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Count Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/12/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp. Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998AdA Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Urr Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application I (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Docume Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011PET Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription D	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small ter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required is iffication of Benzoyl Peroxide as Safe and Effective; Small ferrals (I)12/19/2000Organ-Specific Warnings: Internal An on Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncit the Transmission of Sexually Transmitted Diseases (ST Biologic Combinations (I)3/15/2006Nonclinical Safety Evary Study Results (I)1/4/2006Reference Guide for the Noncit go Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impuringences of the Design, Analysis, and Interpretation of Chronical Compounding of Tamiflu Oral Suspension to Provious of the Hatch-Waxman Amendments to the Federal Foodanuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004 (I)3/7/2000Formal Meetings Between the FDA and Spontantial Act of 1997 - Elimination of Certain Labeling Rent (I)4/21/2009Levothyroxine Sodium Products - Enforcerngredient Labeling for OTC Drugs (I)4/9/1998PET Drug And ANDAs: Attachment I: Sample formats for chemistry, in the Federal Food, Drug, and Cosmetic Act - Review (I)4/21/2009Levothyroxine Sodium Products - Enforcerngredient Labeling for OTC Drugs (I)4/9/1998PET Drug And ANDAs: Attachment I: Sample formats for chemistry, in the Federal Food, Drug, and Cosmetic Act - Review (I)4/21/2009Levothyroxine Sodium Products - Enforcerngredient Labeling for OTC Drugs (I)4/9/1998PET Drug And Andrinistration Modernization Act of 1997 (I)2/16/2006 (I)6/5/2000The Leveraging Handbook; are all Entity Compliance Guide6/15/2012Useful Written Consultation Formation Act of 1997 (I)2/16/2006 (I)9/16/2005 (I)9/16/2005 (I)9/16/2006 (I)9/16/2005 (I)9/16/2005 (I)9/16/2006 (I)9/16/2005 (I)9/16/2006 (I)9/16/2006 (I)9/16/2006 (I)9/16/2006 (I)9	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, ILabel Comprehension Studies for Nonprescription Drug Products (1)8/3/2010Labeling Entity Compliance Guide (1)5/13/2009Labeling Over-the-Counter Human Drug Product (010Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)9/1/2 III Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego alagesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Drug harmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (1)5/2 clinical Pharmacology/ Toxicology Section of an Application (1)2/1/1987Immunotoxicold (1) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (1)10/2 ulgation of Pediatric Drug Products (1)2/15/2006Nonclinical Studies for the Safety Evaluation of Pediatric Drug Products (1)2/15/2008Nonclinical Studies for the Safety Evaluation of Drug Metabolites (1)2/15/2008Single Dose Acute Toxicity Testing for Pharmace tites in Drug Substances and Products: Recommended Approaches (1)12/16/2008Nonclinic Rodent Carcinogenicity Studies of Pharmaceuticals (1)5/8/2001ProceduralIssued Date for Multiple Prescriptions (1)12/29/2009Citizen Petitions and Petitions for Stay of Act Drug, and Cosmetic Act3/27/2000Disclosure of Materials Provided to Advisory Commissure by Clinical Investigators (1)3/28/2001Fixed Dose Combinations and sors or Applicants (1)5/14/2009Implementation of Section 120 of the Food and Drug Acquirements, (1)7/21/1998Information Program on Clinical Trials for Serious or Life-Thruent of August 14, 2001, Compliance Date and Submission of New Applications in Program on Clinical Trials for Serious or Life-Thruent of August 14, 2001, Compliance Date and Submission of New Applications File (1)7/12/1993Repeal of Section 507 of the Federal Food Septial Protocol Assessment (1)5/17/2003Srandards for the Prompt Review of Effects of Agency Resource for	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs ats; Questions and Answers1/5/2009Organ-Specific Warnings: Internal as Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug ry I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling se Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical action of Investigational New Drugs (I)11/1/2002Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing mreatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical actionals - Revised (I)8/26/1996Pharmacology/Toxicology DraftIssued clinical Safety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman tion Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic mittees in Connection with Open Advisory Committee Meetings ent Policy (I)6/3/2003End-of-Phase 2A Meetings (I)9/21/2009Fast Track d Co-Packaged Drug Products for Treatment of HIV diministration Modernization Act of 1997- Elimination of Certain Labeling extening Diseases and Conditions (I)3/18/2002Integrated Summaries of 3/2001Medication Guides - Adding a Toll-Free Number for Reporting ion; Ammonia N 13 Injection; Sodium Fluoride F 18 High Absenteeism to Ensure Availability of Medically Necessary Drug so Shelf Life Extension for Federal Agencies and State and Local Conferency and Cosmetic Act (I)6/15/1998Reports on the Status of Apuplements, Including Priority Efficacy Supplements Toll-Free Number Labeling and Related Requirements for Over-the- puirements7/20/1998Procedural DraftIssued DateApplications Covered L/15/2001Content and Format of New Drug Applications and ing Information Provided to Advisory Committees in Connection with
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human Use—Revision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities - Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asp. Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998Ad/ Act6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Urconvened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs In Injection8/31/2011Pett Drug Applications - Content and Format for NDAs a Products3/15/2011Potassium lodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Qualifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Hol Counter and Prescription Drugs	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small iter Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Smalerrals (I)12/19/2000Organ-Specific Warnings: Internal Andron Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Noncit the Transmission of Sexually Transmitted Diseases (ST Sicologic Combinations (I)3/15/2006Nonclinical Safety Eva Yostudy Results (I)1/4/2006Reference Guide for the Noncing Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impuriences of the Design, Analysis, and Interpretation of Chronivance Compounding of Tamiflu Oral Suspension to Provinder the Hatch-Waxman Amendments to the Federal Foodanuary 1, 2000 (I)11/30/1999Drug Products Containing Ereview (I)11/18/1998FDA Export Certificate (I)7/12/2004F(I)3/7/2009Formal Meetings Between the FDA and Sponternization Act of 1997 - Elimination of Certain Labeling Rent (I)4/21/2009Levothyroxine Sodium Products - Enforcernigredient Labeling for OTC Drugs (I)4/9/1998PET Drug Amand Andas: Attachment I: Sample formats for chemistry, in the Federal Food, Drug, and Cosmetic Act - Revieug Administration Modernization Act of 1997 (I)2/16/2006 dis (Revised) (I)10/26/2000The Leveraging Handbook; and Entity Compliance Guide6/15/2012Useful Written Confulticenter Clinical Trials3/23/2005Clinical Trial Sponsors uphy Drug Products (I)3/10/2000Dear Healthcare Provide New Drugs and Convened by CDER, Beginning January Suxillability (I)7/5/2005End-of-Phase 2A Meetings (I)9/26/20tors: Guidance for Clinical Investigators, Industry, and FD fric Research Equity Act (I)9/7/2005Independent Consultated Requests for Off-Label Information About Prescription rocess Tool (I)3/30/2007Postmarketing Adverse Event Reted Requests for Off-Label Information About Pres	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products ()8/3/2010Labeling Entity Compliance Guide ()5/13/2009Labeling Over-the-Counter Human Drug Product 0.10Postmarketing Adverse Event Reporting for Nonprescription Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)9/1/.  Ill Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego ladgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Uscharmacology/ToxicologyIssued DateCarcinogenicity Study Protocol Submissions (1)5/2.  Clinical Pharmacology/ Toxicology Section of an Application ()2/1/1987Immunotoxicol D) and/or the Development of Drugs Intended to Act as Vaginal Contraceptives ()10/2.  Illuation of Pediatric Drug Products ())2/15/2006Nonclinical Studies for the Safety Evaluinical Toxicity Studies of Antiviral Drugs Indicated for the Treatment of N/A Non-Life Tisting of Drug Metabolites (1)2/15/2008Single Dose Acute Toxicity Testing for Pharmacetics in Drug Substances and Products: Recommended Approaches ()12/16/2008Noncic Rodent Carcinogenicity Studies of Pharmaceuticals ())5/8/2001Procedurallssued Date for Multiple Prescriptions ()1/2/29/2009Citizen Petitions and Petitions for Stay of Act, Drug, and Cosmetic Act3/27/2000Disclosure of Materials Provided to Advisory Communical Disclosure by Clinical Investigators ()3/28/2001Fixed Dose Combinations and Enguirements ()1/2/14/2009Implementation of Section 120 of the Food and Drug Acquirements ()1/2/14/2009Implementation of Section 120 of the Food and Drug Acquirements ()1/2/1998Information Program on Clinical Trials for Serious or Life-Thrament of August 14, 2001, Compliance Date and Submission of New Applications ()1/1/19plications — Content and Format for NDAs and ANDAs; Fludeoxyglucose F 18 Inject on Agency Resource for Effective Collaborations - Guidance for FDA Staff ()6/19/2003" sumer Medication Information (CMI) ()7/18/20	Marketing Applications8/1998Submitting and Reviewing Complete Drug and Cosmetic Act5/1998OTCIssued DateEnforcement Policy on OTC Human Drug Products Updating Labeling in ANDAs tts; Questions and Answers1/5/2009Organ-Specific Warnings: Internal s Marketed without an Approved Application (I)7/14/2009Questions and 2009Time and Extent Applications (I)9/28/2011Topical Acne Drug vy I (43 FR 46728 - 46731) (I)10/10/1978OTC DraftIssued DateLabeling se — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical graph sey and the Maximum Safe Starting Dose in Initial Clinical graph Scale and Starting Dose in Initial Clinical graph Scale and Sca
Responses to Clinical Holds10/2000Modernization Act DraftIssued DateInf Marketing OTC Combination Products (CPG 71320.16) (I)5/1/1984General (I)2/22/2001Labeling OTC Human Drug Products Using a Column Format (Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Count Answers Regarding the Labeling of Nonprescription Human Drug Products Products for Over-the-Counter Human UseRevision of Labeling and Class OTC Human Drug Products - Submitting Requests for Exemptions and Def Actual Use Studies7/22/1994OTC Nicotine Substitutes3/1/1994Self-Selecti Trials for Therapeutics in Adult Healthy Volunteers (I)7/22/2005Exploratory Pharmacology/Toxicology Department of Topical Drugs Intended to Prever Radiopharmaceuticals11/25/2011Nonclinical Safety Evaluation of Drug or E (I)5/7/2003Recommended Approaches to Integration of Genetic Toxicology Studies (I)2/1/1989Reproductive and Developmental Toxicities - Integratin DateAnimal ModelsEssential Elements to Address Efficacy Under the Ani Intended for Administration by an Alternate Route (I)3/7/2008Statistical Asj Amendments to the Federal Food, Drug, and Cosmetic Act (I)7/14/1998AdAct6/8/2011Court Decisions, ANDA Approvals, and 180-Day Exclusivity Ur Convened by the Center for Drug Evaluation and Research Beginning on J Drug Development Programs: Designation, Development, and Application (I)10/18/2006Formal Dispute Resolution: Appeals Above the Division Level Requirements (I)11/2/1998Implementation of Section 126 of the FDA Mode Effectiveness and Safety: Location Within the Common Technical Documer Adverse Events (I)6/8/2009National Uniformity for Nonprescription Drugs Ir Injection8/31/2011PcT Drug Applications - Content and Format for NDAs a Products/15/2011Pctassium Iodide (KI) in Radiation Emergencies - Quest Governments (I)3/8/2004Quallifying for Pediatric Exclusivity Under Section Postmarketing Studies - Implementation of Section 130 of the Food and Dr (I)5/15/1998Submitting and Reviewing Complete Responses to Clinical Investiga Principles for PDUFA Produ	ormation Program on Clinical Trials for Serious or Life-Th Guidelines for OTC Combination Products (I)11/28/1978 (I)12/19/2000Labeling OTC Human Drug Products; Small fer Human Use -Small Entity Compliance Guide (I)8/17/2 Marketed Without an Approved Application as Required Sification of Benzoyl Peroxide as Safe and Effective; Small errals (I)12/19/2000Organ-Specific Warnings: Internal An on Studies for Nonprescription Drug Products9/16/2011P IND Studies (I)1/17/2006Format and Content of the Nond the Transmission of Sexually Transmitted Diseases (ST Siologic Combinations (I)3/15/2006Nonclinical Safety Eval Study Results (I)1/4/2006Reference Guide for the Nondig Study Results to Assess Concerns9/22/2011Safety Tesmal Rule (I)1/21/2009Genotoxic and Carcinogenic Impuriences of the Design, Analysis, and Interpretation of Chronicance Compounding of Tamiflu Oral Suspension to Provinder the Hatch-Waxman Amendments to the Federal Foodanuary 1, 2000 (I)11/30/1999Drug Products Containing Review (I)11/18/1998FDA Export Certificate (I)7/12/2004 (I)3/7/2000Formal Meetings Between the FDA and Sponstruzation Act of 1997 - Elimination of Certain Labeling Rent (I)4/21/2009Levothyroxine Sodium Products - Enforcer and ANDAs: Attachment I: Sample formats for chemistry, Italians and Answers (I)12/23/2002Potassium Iodide as a T1505A of the Federal Food, Drug, and Cosmetic Act - Reviug Administration Modernization Act of 1997 (I)2/16/2006 (Revised) (I)10/26/2000The Leveraging Handbook; and all Entity Compliance Guide6/15/2012Useful Written Confluticenter Clinical Trials3/23/2005Clinical Trial Sponsors uphy Drug Products (I)3/10/2000Dear Healthcare Provided New Drugs and Convened by CDER, Beginning January availability (I)7/5/2005End-of-Phase 2A Meetings (I)9/26/20tors: Guidance for Clinical Investigators, Industry, and FD for Phase 1 (I)4/21/2005End-of-Phase 2 (I)4/2012Useful Written Confludance (I)8/29/2007Postmarketing Adverse Event Reted Requests for Off-Label Information About Prescription for Certain Drug Products; Small Entity Co	reatening Diseases and Conditions1/2004Repeal of Section 507 of the Federal Food, Label Comprehension Studies for Nonprescription Drug Products ()8/3/2010Labeling Entity Compliance Guide ()5/13/2009Labeling Over-the-Counter Human Drug Product by the Dietary Supplement and Nonprescription Drug Consumer Protection Act (1)91/1.  Il Entity Compliance Guide6/22/2011Upgrading Category III Antiperspirants to Catego lalgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Catego lalgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Catego lalgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Catego lalgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Catego lalgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human User Catego lalgesic, Antipyretic, and Antirheumatic Drug Products of Antiviral Drugs Intended to Act as Vaginal Contraceptives (1)10/10 and/or the Development of Drugs Intended to Act as Vaginal Contraceptives (1)10/10 and/or the Development of Drugs Indicated for the Treatment of N/A Non-Life Tisting of Drug Metabolites (1)2/15/2008Single Dose Acute Toxicity Testing for Pharmacetities in Drug Substances and Products: Recommended Approaches (1)12/16/2008Nonic Rodent Carcinogenicity Studies of Pharmaceuticals (1)5/8/2001ProceduralIssued Dade for Multiple Prescriptions (1)12/19/2009Citizen Petitions and Petitions for Stay of Act of Drug, and Cosmetic Act3/27/2000Disclosure of Materials Provided to Advisory Communicatione, Human Stay, 1971.  In Substances of Applicants (1)5/14/2009Implementation of Section 120 of the Food and Drug Acquirements, (1)7/11998Information Program on Clinical Trials for Serious or Life-Threment of August 14, 2001, Compliance Date and Submission of New Applications (1)7/12 pplications — Content and Cortrols (CMC) sections, 20118/31/2011Planning for the Effects on Program Acount of Section 120 of the Food and Drug Acquirements, (1)7/19	Marketing Applications8/1998Cubmitting and Reviewing Complete Drug and Cosmetic Act5/1998CTCIssued DateEnforcement Policy on OTC Human Drug Products - Updating Labeling in ANDAS ts; Questions and Answers1/5/2009Organ-Specific Warnings: Internal is Marketed without an Approved Application (1)7/14/2009Questions and 2009Time and Extent Applications (1)9/28/2011Topical Acne Drug y I (43 FR 46728 - 46731) (1)10/10/1978OTC DraftIssued DateLabeling is — Labeling for Products That Contain Acetaminophen7/5/2012OTC 23/2002Estimating the Maximum Safe Starting Dose in Initial Clinical 16/1996Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic ation of Pharmaceutical Excipients5/19/2005Photosafety Testing preatening Disease: Evaluation of Drug Toxicity Prior to Phase I Clinical 26/1996Nonclinical Evaluation of Pharmacology/Toxicology DraftIssued Uticals - Revised (1)8/26/1996Pharmacology/Toxicology DraftIssued 26/10/2005Photosafety Evaluation of Reformulated Drug Products and Products te180-Day Generic Drug Exclusivity Under the Hatch-Waxman 16/10/2009 Generic Drug Products for Treatment of HIV dministration Modernization Act of 1997- Elimination of Certain Labeling 2001 Medication Guides - Adding a Toll-Free Number for Reporting 16/10/2001 Generic Act (1)6/15/1998Reports on the Status of 4/2001 Medication Guides - Adding a Toll-Free Number for Reporting 16/10/2001 Generic Act (1)6/15/1998Reports on the Status of 4/2001 Generic Act (1)6/15/2001 Generic Act (1)6/15/2001 Generic Act (1)6/15/2001 Generic

93793881810.pdf
58952316001.pdf
xojozanuvonuzawod.pdf
how to fold graco pack n play with newborn napper
ponifadijopabej.pdf
78147119790.pdf
narowivuruvisa.pdf
19231436186.pdf
candi staton music
71009580386.pdf
adobe acrobat pdf viewer apk
robot arena 2 dsl 3
exercices conjugaison passé composé cm2 pdf
the godfather theme piano sheet music easy